Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae offers BRCA1/BRCA2 testing, providing clinicians with a reliable, fast, affordable option for patients

Invitae offers BRCA1/BRCA2 testing, providing clinicians with a reliable, fast, affordable option for patients

December 11, 2013

SAN ANTONIO, December 11, 2013 – Invitae Corporation, a genetic diagnostics company, today announced at the 2013 San Antonio Breast Cancer Symposium that it now offers BRCA1 and BRCA2 testing globally, providing clinicians with a reliable, fast and affordable option for their cancer patients.  Available with a turnaround time of just two weeks, this test includes full gene sequencing for both BRCA1 and BRCA2, as well as deletion/duplication analysis.  The test is globally available and is priced at ...

Read more


Invitae completes $40 million series E financing

Invitae completes $40 million series E financing

December 10, 2013

SAN FRANCISCO, December 10, 2013 - Invitae Corporation, a genetic diagnostics company, today announced the completion of a $40 million Series E financing. Invitae will use the financing to accelerate the ongoing development of the company’s clinical genetic tests for hereditary disorders, including oncology, neurology and pediatric medicine. Invitae will also focus on expanding to international markets.

Investors participating in the Series E round include Genomic Health, Inc. (NASDAQ: GHDX), Randy Scott, Thomas McNerney & Partners, Redmile Group, Genesys Capital, Casdin ...

Read more


Invitae files suit against Myriad Genetics

Invitae files suit against Myriad Genetics

December 02, 2013

SAN FRANCISCO, December 2, 2013 – Invitae Corporation, a genetic diagnostics company, today announced that it filed an action in the U.S. District Court for the Northern District of California against Myriad Genetics, Inc. (NASDAQ: MYGN).  By its suit, Invitae seeks a declaration that certain Myriad patents relating to the BRCA1, BRCA2 and MUTYH genes are invalid and are not infringed by Invitae. 

Invitae’s announcement today reinforces its commitment to defend its right to provide naturally occurring ...

Read more


Invitae responds to Myriad Genetics lawsuit

Invitae responds to Myriad Genetics lawsuit

November 26, 2013

SAN FRANCISCO, November 26, 2013 – Invitae Corporation, a genetic diagnostics company, today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through its genetic testing services.  Invitae has been named a defendant in a lawsuit filed by Myriad Genetics, Inc. regarding Invitae’s BRCA and MUTYH genetic tests. Invitae disagrees with the allegations of the lawsuit and plans to vigorously defend itself against the lawsuit, which ...

Read more


Invitae Chile, presenting the "Future of Genetic Medicine" in Santiago

Invitae Chile, presenting the "Future of Genetic Medicine" in Santiago

September 20, 2013

SANTIAGO, CHILE – September 20, 2013 - Invitae Corporation, headquartered in San Francisco, California, has announced that Genometrics, a Chilean company located in Santiago, will be the exclusive partner for the Invitae Chile SpA in Chile.  Invitae is a genetic diagnostics company specializing in genetic testing for hereditary diseases in oncology, cardiology, neurology and pediatric medicine.  Invitae previously announced that it will have a fully operational laboratory for the purpose of providing these tests for the Latin American ...

Read more


Invitae announces results of hereditary breast cancer study in collaboration with Stanford University

Invitae announces results of hereditary breast cancer study in collaboration with Stanford University

September 07, 2013

Presentation at ASCO Breast Symposium demonstrates that next-generation DNA sequencing technology accurately identifies BRCA 1 and 2 mutations and multi-gene testing adds value beyond BRCA 1 and 2 for cancer patients.

SAN FRANCISCO, CA -  September 07, 2013 -  Invitae, Inc., a genetic information company, today announced the results of a study conducted in collaboration with Stanford University assessing hereditary breast and ovarian cancer risk using a multi-gene next-generation sequencing panel. The results showed that analysis of BRCA1/2 mutations produced ...

Read more


International initiative applauds the Supreme Court decision eliminating gene patents and announces the launch of a public database for hereditary gene mutations

International initiative applauds the Supreme Court decision eliminating gene patents and announces the launch of a public database for hereditary gene mutations

June 13, 2013

SAN FRANCISCO, CA - June 13, 2013 - A consortium of policy makers, advocacy organizations, individuals, academic centers and industry today announced the formation of a first-of-its kind initiative, Free the Data!, to fill the public information gap caused by the lack of available genetic information for the BRCA1 and BRCA2 genes and plans to expand to provide other types of genetic information in open, searchable databases, including the National Center for Biotechnology Information’s database, ClinVar.  The primary founders ...

Read more


Invitae establishes an international subsidiary and state-of-the-art genetic testing facility in Chile, partnership with biotech pioneer, Pablo Valenzuela

Invitae establishes an international subsidiary and state-of-the-art genetic testing facility in Chile, partnership with biotech pioneer, Pablo Valenzuela

May 30, 2013

SANTIAGO, CHILE - May 30, 2013 - Invitae Corporation announced today the establishment of a South American subsidiary, Invitae Chile SpA, and a partnership with biotechnology pioneer, Pablo Valenzuela and the Fundación Ciencia & Vida, to establish a production facility in Santiago, Chile. Dr. Valenzuela is a well-known biotechnology entrepreneur who co-founded Chiron in 1981 and the Fundacion in 1997.

The new entity is being formed to service global markets with genetic information that will inform routine medical practice and influence ...

Read more